- Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT)
- The latest investment increases the cumulative investment to US$1 million
- Negev believes the company’s expertise, cash on hand and progress with clinical trials makes it a singular investment opportunity
- Small Pharma is a neuropharmaceutical company specialized in IP-led development of treatments for mental health conditions
- Small Pharma (DMT) is unchanged trading at $0.36 per share
Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT).
The latest investment increases the cumulative investment to US$1 million.
Negev invests in companies developing novel drugs for psychiatric disorders based on psychedelic compounds. Since its inception in February 2021, the fund has recorded exceptional performance through fifteen investments across the U.S., Canada and Europe valued at over US$20 million.
In February 2021, Small Pharma initiated a clinical program into DMT-assisted therapy. This program includes a Phase I/IIa trial on its lead candidate alongside the development of a robust pipeline of proprietary preclinical assets.
Peter Rands, Small Pharma’s CEO, stated,
“Negev Capital’s ongoing investment in our company is a vote of confidence in our robust pipeline of proprietary assets. Small Pharma’s performance to date is a reflection of our team’s capabilities and potential.”
Ken Belotsky, Partner at Negev Capital, added,
“Small Pharma’s recent market cap of circa US$100 million, including approximately US$42 million in cash, is an exceptional investment opportunity giving consideration to the strong science team and progress in clinical trials. We are excited to play a crucial role in helping such companies to achieve their goals.”
Small Pharma is a neuropharmaceutical company specialized in IP-led development of treatments for mental health conditions.
Small Pharma (DMT) is unchanged trading at $0.36 per share as of 2:22 pm ET.
